.Attribute Medication, Released online: 16 September 2024 doi:10.1038/ s41591-024-03244-8In the empirical SCRUM-Japan GOZILA research study, after a median follow-up of 11 months, people along with metastatic stomach tumors that received biomarker-matched treatments based on flowing cyst DNA profiling showed a more significant medical benefit than those receiving unmatched therapy.